Table 2.
Efficacy of three different first-line regimens in patients with unresectable pancreatic cancer.
| Nab-Paclitaxel-Gemcitabine | mFOLFIRINOX | GEMOX | p-Value | |
|---|---|---|---|---|
| Total cases | 62 | 30 | 25 | |
| treatment cycles (median) | 4 | 6 | 4 | |
| PR, n (%) | 15(24) | 8(27) | 8(32) | 0.76 |
| SD, n (%) | 36(58) | 10(33) | 8(32) | 0.02 |
| PD, n (%) | 11(18) | 12(40) | 9(36) | 0.04 |
| ORR a, n (%) | 15(24) | 8(27) | 8(32) | 0.76 |
| DCR b, n (%) | 51(82) | 18(60) | 16(64) | 0.04 |
| Median PFS (months) | 4.9 | 3.7 | 4.7 | 0.35 |
| 6 mo (%) | 34.5 | 25.6 | 40.1 | 0.47 |
| 12 mo (%) | 9.2 | 4.3 | 26.8 | 0.44 |
| Median OS (months) | 11.1 | 10.1 | 10.2 | 0.75 |
| 6 mo (%) | 79.6 | 67.2 | 83.5 | 0.14 |
| 12 mo (%) | 47.0 | 39.6 | 37.6 | 0.88 |
| 18 mo (%) | 23.6 | 19.8 | 12.5 | 0.87 |
| 24 mo (%) | 8.8 | 6.6 | 8.3 | 0.73 |
a ORR is defined as the percentage of patients who had a CR or PR. b DCR is defined as the. percentage of patients who had a CR, PR, or SD. Abbreviations: PR, Partial response; SD, Stable disease; PD, Progressive disease; ORR, Rate of objective response; DCR, Rate of disease control; OS, overall survival; PFS, progression-free survival. Gem, gemcitabine.